|
End-of-day quote
Shenzhen S.E.
14/08/2026
|
5-day change | 1st Jan Change | ||
| 11.61 CNY | -0.43% |
|
+4.22% | -4.44% |
| 05-22 | Zhuhai Rundu Pharmaceutical Wins China Approval for Pain Relief Drug | MT |
| 05-19 | China Grants Zhuhai Rundu Pharmaceutical Marketing Approval for Hypertension Drug | MT |
Company Valuation: Zhuhai Rundu Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2,999 | 4,552 | 4,186 | 4,133 | 3,195 | 4,069 |
| Change | - | 51.79% | -8.03% | -1.28% | -22.69% | 27.36% |
| Enterprise Value (EV) 1 | 2,772 | 4,588 | 4,433 | 4,491 | 3,489 | 4,345 |
| Change | - | 65.48% | -3.37% | 1.31% | -22.32% | 24.54% |
| P/E | 21.8x | 32.2x | 26.9x | 61.7x | 79.5x | -63.9x |
| PBR | 2.89x | 4.09x | 3.5x | 3.5x | 2.77x | 3.92x |
| PEG | - | 11.9x | 2.4x | -1.1x | -2x | 0x |
| Capitalization / Revenue | 2.39x | 3.83x | 3.05x | 3.2x | 2.7x | 3.46x |
| EV / Revenue | 2.21x | 3.86x | 3.23x | 3.48x | 2.95x | 3.69x |
| EV / EBITDA | 15.6x | 23.1x | 18.8x | 24.5x | 20.1x | 37.9x |
| EV / EBIT | 21.8x | 33.1x | 26.7x | 62.1x | 88.3x | -164x |
| EV / FCF | -24.5x | -22.2x | -34.3x | -33.4x | 27.7x | 39.5x |
| FCF Yield | -4.07% | -4.51% | -2.92% | -2.99% | 3.61% | 2.53% |
| Dividend per Share 2 | 0.2198 | 0.2198 | 0.25 | 0.2 | 0.15 | - |
| Rate of return | 2.48% | 1.63% | 2% | 1.62% | 1.57% | - |
| EPS 2 | 0.4066 | 0.4176 | 0.4643 | 0.2 | 0.12 | -0.19 |
| Distribution rate | 54.1% | 52.6% | 53.8% | 100% | 125% | - |
| Net sales 1 | 1,253 | 1,190 | 1,372 | 1,292 | 1,182 | 1,176 |
| EBITDA 1 | 177.3 | 198.4 | 235.5 | 183.2 | 173.3 | 114.6 |
| EBIT 1 | 127.3 | 138.5 | 166 | 72.31 | 39.52 | -26.57 |
| Net income 1 | 135.9 | 139.8 | 155.5 | 66.9 | 39.88 | -63.47 |
| Net Debt 1 | -226.3 | 36.22 | 247.3 | 358.9 | 294 | 276.1 |
| Reference price 2 | 8.86 | 13.47 | 12.50 | 12.34 | 9.54 | 12.15 |
| Nbr of stocks (in thousands) | 338,359 | 337,992 | 334,893 | 334,893 | 334,893 | 334,893 |
| Announcement Date | 22/04/21 | 18/04/22 | 27/04/23 | 27/04/24 | 28/04/25 | 27/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 576M | |
| 34.32x | 12.47x | 25.45x | 0.57% | 1,052B | |
| 29.15x | - | - | 2.05% | 627B | |
| 32.02x | 7.45x | 15.48x | 2.73% | 441B | |
| 20.19x | 4.79x | 11.87x | 2.76% | 349B | |
| 21.62x | 5.6x | 13.97x | 2.87% | 287B | |
| 20.24x | 4.18x | 11.87x | 2.1% | 241B | |
| 26.43x | 6.88x | 12.21x | 2.41% | 224B | |
| 13.48x | 4.84x | 10.07x | 3.78% | 202B | |
| -42.9x | 6.13x | 34.58x | 2.39% | 172B | |
| Average | 17.17x | 6.54x | 16.94x | 2.41% | 359.58B | |
| Weighted average by Cap. | 24.46x | 8.18x | 18.64x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002923 Stock
- Valuation Zhuhai Rundu Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
